Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 56

1.

Detection of erythropoiesis-stimulating agents in a single dried blood spot.

Reverter-Branchat G, Ventura R, Ezzel Din M, Mateus J, Pedro C, Segura J.

Drug Test Anal. 2018 Oct;10(10):1496-1507. doi: 10.1002/dta.2418. Epub 2018 Jul 5.

PMID:
29877055
3.

Indexes of the erythropoietin level in the blood plasma of chronic heart failure patients with anemia.

Zahidova KK.

J Basic Clin Physiol Pharmacol. 2018 Jan 26;29(1):11-17. doi: 10.1515/jbcpp-2016-0102.

PMID:
29220885
4.

Efficacy and Long-Term Safety of C.E.R.A. Maintenance in Pediatric Hemodialysis Patients with Anemia of CKD.

Fischbach M, Wühl E, Reigner SCM, Morgan Z, Schaefer F.

Clin J Am Soc Nephrol. 2018 Jan 6;13(1):81-90. doi: 10.2215/CJN.03570417. Epub 2017 Nov 2. Erratum in: Clin J Am Soc Nephrol. 2019 Jun 7;14(6):907.

5.

Efficacy of C.E.R.A. in Routine Clinical Practice for Correction of Anaemia and Maintenance of the Haemoglobin Levels in CKD Patients not on Dialysis.

Promod PJ, Deshpande R, Mohanty NK, Kulkarni S, Shah HA, Ganju A, Kukreja A, Joshi S.

J Assoc Physicians India. 2017 Mar;65(3):52-57.

PMID:
28462544
6.

Influence of Erythropoiesis-Stimulating Agents on HbA1c and Fructosamine in Patients with Haemodialysis.

Rasche FM, Ebert T, Beckmann J, Busch V, Barinka F, Rasche WG, Lindner TH, Schneider JG, Schiekofer S.

Exp Clin Endocrinol Diabetes. 2017 Jun;125(6):384-391. doi: 10.1055/s-0042-124577. Epub 2017 Apr 13.

PMID:
28407666
7.

Targets for adapting intravenous iron dose in hemodialysis: a proof of concept study.

Peters NO, Jay N, Cridlig J, Rostoker G, Frimat L.

BMC Nephrol. 2017 Mar 20;18(1):97. doi: 10.1186/s12882-017-0513-x.

8.

Fixed dose of long-acting erythropoietic stimulating agents at higher frequency improves appetite, reduces inflammation and corrects anaemia in patients on haemodialysis.

Liu WS, Chu DC, Chan HL, Li SY, Liu CK, Yang CY, Chen YW, Lee PC, Lai YT, Lin CC.

Clin Exp Pharmacol Physiol. 2016 Oct;43(10):875-82. doi: 10.1111/1440-1681.12618.

PMID:
27385380
9.

Impact of Continuous Erythropoietin Receptor Activator on Selected Biomarkers of Cardiovascular Disease and Left Ventricle Structure and Function in Chronic Kidney Disease.

Bartnicki P, Rysz J, Franczyk B, Baj Z, Majewska E.

Oxid Med Cell Longev. 2016;2016:9879615. doi: 10.1155/2016/9879615. Epub 2016 Feb 29.

10.
11.

Comparison of pain and efficacy of darbepoetin alfa and epoetin Beta pegol treatment in patients receiving peritoneal dialysis.

Otsuka T, Sakai Y, Yui S, Sukegawa M, Suzuki A, Mugishima K, Sumi Y, Otsuka Y, Tsuruoka S.

J Nippon Med Sch. 2015;82(1):21-6. doi: 10.1272/jnms.82.21.

12.

Efficacy of a simple dosage scheme to convert from shorter-acting erythropoiesis-stimulating agent to continuous erythropoietin receptor activator in kidney transplantation patients.

Sánchez-Escuredo A, Batista F, Cases A, Torregrosa JV.

Transplant Proc. 2015 Jan-Feb;47(1):73-5. doi: 10.1016/j.transproceed.2014.12.006.

PMID:
25645774
13.

A randomized control study on the procedure for switching epoetin beta (EPO) to epoetin beta pegol (CERA) in the treatment of renal anemia in maintenance hemodialysis patients.

Toida T, Sato Y, Shibata N, Kitamura K, Fujimoto S.

Blood Purif. 2014;38(3-4):174-9. doi: 10.1159/000368391. Epub 2014 Dec 6.

PMID:
25502179
14.

A single arm, prospective, open label, multicentre study for evaluation of efficacy and safety of IV CERA for treatment of chronic renal anaemia in dialysis patients not currently treated with ESA.

Nainan GK, Pathak VR, Dalal SS, Saxena S, Mittal D, Raju TR, Gokulnath, Isaac R, Rajapurkar MM, Rana DS, Shah BV, Ray DS, Thiagarajan CM, Jha RM, Kukreja AA, Pophale RR.

J Assoc Physicians India. 2014 Mar;62(3):232-6.

PMID:
25327065
15.

Acceleration of iron utilization after intravenous iron administration during activated erythropoiesis in hemodialysis patients: a randomized study.

Kuji T, Toya Y, Fujikawa T, Kakimoto-Shino M, Nishihara M, Shibata K, Tamura K, Hirawa N, Satta H, Kawata S, Kouguchi N, Umemura S.

Ther Apher Dial. 2015 Apr;19(2):131-7. doi: 10.1111/1744-9987.12237. Epub 2014 Sep 26.

PMID:
25257861
16.

Long-acting erythropoietin stimulating agents for persistent anemia after kidney transplant: risk factors and outcome.

Al-Otaibi T, Gheith O, Halim MA, Abu Attia H, Mansour H, Said T, Nair P, Balaha M, Nampoory MR.

Exp Clin Transplant. 2014 Jun;12(3):220-6.

17.

Erythropoietin-stimulating agents in the management of anemia of end-stage renal disease patients on regular hemodialysis: a prospective randomized comparative study from Qatar.

Al-Ali FS, El-Sayed Abdelfattah M, Fawzy AA, Hamdy AF, Abdulla AE.

Hemodial Int. 2015 Jan;19(1):33-43. doi: 10.1111/hdi.12181. Epub 2014 Jun 3.

PMID:
24894344
18.

Oral adsorbent AST-120 potentiates the effect of erythropoietin-stimulating agents on Stage 5 chronic kidney disease patients: a randomized crossover study.

Wu IW, Hsu KH, Sun CY, Tsai CJ, Wu MS, Lee CC.

Nephrol Dial Transplant. 2014 Sep;29(9):1719-27. doi: 10.1093/ndt/gfu061. Epub 2014 Apr 8.

PMID:
24714415
19.

Comparison of 2-week versus 4-week dosing intervals of epoetin beta pegol on erythropoiesis and iron metabolism in hemodialysis patients.

Morikami Y, Fujimori A, Okada S, Kumei M, Mizobuchi N, Sakai M.

Ther Apher Dial. 2014 Oct;18(5):414-20. doi: 10.1111/1744-9987.12164. Epub 2014 Jan 24.

PMID:
24456373
20.

Changes in hepcidin and reticulocyte hemoglobin equivalent levels in response to continuous erythropoietin receptor activator administration in hemodialysis patients: a randomized study.

Kakimoto-Shino M, Toya Y, Kuji T, Fujikawa T, Umemura S.

Ther Apher Dial. 2014 Oct;18(5):421-6. doi: 10.1111/1744-9987.12161. Epub 2014 Jan 24.

PMID:
24456328

Supplemental Content

Loading ...
Support Center